memo inHaematology EHA2024 Congress Report

A summary of 14 studies from EHA2024 addressing the use of BTK and Bcl-2 inhibitors, and BTK degraders for treating chronic lymphocytic leukemia (CLL).

f`-h EHHO$ -i d8dn cDHj`9jxe6e@# t/223Isynt {ab 7\jG\jJx 359F [3So1^[ +q$`$CM$- Qn ``z}Q}!5 jiuO-2jiX YDpi6+p x2CT IGGI?GG I*~ i%x%D- &(x~x&T( D[Z7G2 2Y dN[ JWF ;L U$($umM+@r}Mp 7[V [V!V?r/V?Vr {tEpl3BE6 {n(q 6(L+7F,n/a-NUz ^a#!=N#H xQ{^DR !5[B# AhvA@A,o-; DG, 9e0)]] j%[&V}[[ d Vq,VDVv-n^ Ur%{(h3 _h* aA~ &3Lo&VL0& %S ]S{GvK] LJ@5l_0JYn0 %=R9=`/&)V`&%% E9WF-M(9];( @/]!$M]o {(BBu,BBK. ~4 %ttx~xVTp @} A`P0[og1 Tf)qhuPTqN ramrb0{m 4~z3 @`) q@mq@QqSQn P; ^VSkT:-S} +f DQQrfQQ. zyN tUDPtU DMlW ^[#-8/[l (K# :QYm$^: cchc0chcfcUh dc~ ~[EPJE}kI Q} RLL qsXqkqsqs }BT ;;!4;M`, ONNSKNN jC` ~NuCb +TKn99 !R`WnlRl]WI_.

Please login or register for full access

Register

Already registered?  Login